288 related articles for article (PubMed ID: 28511645)
21. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
[TBL] [Abstract][Full Text] [Related]
22. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
Watanabe T; Tsuda M; Makino Y; Ichihara S; Sawa H; Minami A; Mochizuki N; Nagashima K; Tanaka S
Mol Cancer Res; 2006 Jul; 4(7):499-510. PubMed ID: 16849525
[TBL] [Abstract][Full Text] [Related]
23. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.
Zhou Y; Shan S; Li ZB; Xin LJ; Pan DS; Yang QJ; Liu YP; Yue XP; Liu XR; Gao JZ; Zhang JW; Ning ZQ; Lu XP
Cancer Sci; 2017 Mar; 108(3):469-477. PubMed ID: 28004478
[TBL] [Abstract][Full Text] [Related]
24. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
Morgan SS; Cranmer LD
BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
[TBL] [Abstract][Full Text] [Related]
25. Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115.
Kunii E; Ozasa H; Oguri T; Maeno K; Fukuda S; Uemura T; Takakuwa O; Ohkubo H; Takemura M; Niimi A
Anticancer Res; 2015 Oct; 35(10):5241-7. PubMed ID: 26408683
[TBL] [Abstract][Full Text] [Related]
26. AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development.
Wan X; Zhou M; Huang F; Zhao N; Chen X; Wu Y; Zhu W; Ni Z; Jin F; Wang Y; Hu Z; Chen X; Ren M; Zhang H; Zha X
Cell Death Dis; 2021 Feb; 12(2):172. PubMed ID: 33568640
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
28. Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Wakamatsu T; Naka N; Sasagawa S; Tanaka T; Takenaka S; Araki N; Ueda T; Nishizawa Y; Yoshikawa H; Itoh K
Cancer Sci; 2014 Sep; 105(9):1124-34. PubMed ID: 24975049
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG; Whalen PM; Soderstrom E; Moraski G; Lyssikatos JP; Wang HF; Cooper B; Baker DA; Savage D; Dalvie D; Atherton JA; Ralston S; Szewc R; Kath JC; Lin J; Soderstrom C; Tkalcevic G; Cohen BD; Pollack V; Barth W; Hungerford W; Ung E
Cancer Res; 2005 Feb; 65(3):957-66. PubMed ID: 15705896
[TBL] [Abstract][Full Text] [Related]
30. Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.
Ekpe-Adewuyi E; Lopez-Campistrous A; Tang X; Brindley DN; McMullen TP
Oncotarget; 2016 Dec; 7(50):83684-83700. PubMed ID: 27845909
[TBL] [Abstract][Full Text] [Related]
31. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
[TBL] [Abstract][Full Text] [Related]
32. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.
Outani H; Tanaka T; Wakamatsu T; Imura Y; Hamada K; Araki N; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2014 Jun; 14():455. PubMed ID: 24946937
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.
Feng H; Li Y; Yin Y; Zhang W; Hou Y; Zhang L; Li Z; Xie B; Gao WQ; Sarkaria JN; Raizer JJ; James CD; Parsa AT; Hu B; Cheng SY
Neuro Oncol; 2015 Jun; 17(6):832-42. PubMed ID: 25468898
[TBL] [Abstract][Full Text] [Related]
34. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Yeramian A; Sorolla A; Velasco A; Santacana M; Dolcet X; Valls J; Abal L; Moreno S; Egido R; Casanova JM; Puig S; Vilella R; Llombart-Cussac A; Matias-Guiu X; Martí RM
Int J Cancer; 2012 Feb; 130(4):967-78. PubMed ID: 21445974
[TBL] [Abstract][Full Text] [Related]
36. Interactions between cadherin-11 and platelet-derived growth factor receptor-alpha signaling link cell adhesion and proliferation.
Madarampalli B; Watts GFM; Panipinto PM; Nguygen HN; Brenner MB; Noss EH
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1516-1524. PubMed ID: 30876808
[TBL] [Abstract][Full Text] [Related]
37. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
38. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
39. SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans.
Zhang L; Zhang W; Li Y; Alvarez A; Li Z; Wang Y; Song L; Lv D; Nakano I; Hu B; Cheng SY; Feng H
Oncogene; 2016 Oct; 35(43):5641-5652. PubMed ID: 27041571
[TBL] [Abstract][Full Text] [Related]
40. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
